Table 2.

Crude and adjusted^a screening and treatment rates among incident CKD patients, by time period

	2004–06	2007–09	2010–12	P for trend
Proteinuria quantification
Person-years follow-up	1185	1308	1369
# Screened patients	211	289	449
Screening rate (95% CI), per 100 py	17.8 (15.6–20.4)	22.1 (19.7–24.8)	32.8 (29.9–36.0)	<0.001
Adjusted screening rate (95% CI), per 100 py	30.8 (27.0–58.3)	39.2 (35.0–43.9)	50.7 (46.3–55.5)	<0.001
Statin treatment
Person-years follow-up	1073	1229	1366
# Treated patients	371	480	590
Treatment rate (95% CI), per 100 py	34.6 (31.2–38.3)	39.1 (35.7–42.7)	43.2 (39.8–46.8)	0.09
Adjusted treatment rate (95% CI), per 100 py	52.6 (47.5–58.3)	62.7 (57.3–68.5)	63.5 (58.6–68.9)	<0.001
ACEI or ARB treatment
Person-years follow-up	106	153	137
# Treated patients	68	80	84
Treatment rate (95% CI), per 100 py	64.3 (50.7–81.5)	52.3 (42.0–65.1)	61.3 (49.5–76.0)	0.84
Adjusted treatment rate (95% CI), per 100 py	88.2 (67.6–115.0)	82.8 (64.3–106.8)	79.9 (61.8–103.2)	0.82
Nephrology referral
Person-years follow-up	1378	1521	1748
# Referred patients	12	20	48
Referral rate (95% CI), per 100 py	0.9 (0.5–1.5)	1.3 (0.8–2.0)	2.7 (2.0–3.6)	<0.001
Adjusted referral rate (95% CI), per 100 py	1.7 (1.0-3.0)	2.6 (1.7–4.1)	5.2 (3.9–6.9)	<0.001

Proteinuria screening and nephrology referral: n = 728, 788 and 956 during Periods 1, 2 and 3, respectively. Statin treatment was limited to those aged 50 years and older at entry: n = 713, 773 and 930 during Periods 1, 2 and 3, respectively. ACEI or ARB treatment was limited to those with an indication (proteinuria): n = 82, 102 and 115 during periods 1, 2 and 3, respectively. CI, confidence interval; py, person-years.

^aStandardized to a 73-year-old male with baseline eGFR of 49 mL/min/1.73 m².